Coherus Biosciences Stock Analysis
| CHRS Stock | USD 0.88 0.03 3.53% |
Coherus BioSciences is undervalued with Real Value of 3.81 and Target Price of 12.63. The main objective of Coherus BioSciences stock analysis is to determine its intrinsic value, which is an estimate of what Coherus BioSciences is worth, separate from its market price. There are two main types of Coherus BioSciences' stock analysis: fundamental analysis and technical analysis.
The Coherus BioSciences stock is traded in the USA on NASDAQ Exchange, with the market opening at 09:30:00 and closing at 16:00:00 every Mon,Tue,Wed,Thu,Fri except for officially observed holidays in the USA. Coherus BioSciences is usually not traded on Memorial Day, Juneteenth Holiday, Independence Day, Labour Day, Thanksgiving Day, Christmas Day, New Year 's Day, Dr . Martin Luther King Jr 's Birthday, Washington 's Birthday, Good Friday. Coherus Stock trading window is adjusted to America/New York timezone.
Coherus |
Coherus Stock Analysis Notes
About 73.0% of the company shares are held by institutions such as insurance companies. The company recorded a loss per share of 0.38. Coherus BioSciences last dividend was issued on the June 26, 1995. The entity had 2:1 split on the December 8, 1992. Coherus BioSciences, Inc., a biopharmaceutical company, focuses on the biosimilar and immuno-oncology market primarily in the United States. Coherus BioSciences, Inc. was incorporated in 2010 and is headquartered in Redwood City, California. Coherus Bio operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 368 people. For more info on Coherus BioSciences please contact Dennis Lanfear at 650 649 3530 or go to https://www.coherus.com.Coherus BioSciences Investment Alerts
| Coherus BioSciences generated a negative expected return over the last 90 days | |
| Coherus BioSciences has high historical volatility and very poor performance | |
| Coherus BioSciences has some characteristics of a very speculative penny stock | |
| Coherus BioSciences has high likelihood to experience some financial distress in the next 2 years | |
| The company reported the previous year's revenue of 257.24 M. Net Loss for the year was (237.89 M) with loss before overhead, payroll, taxes, and interest of (58.4 M). | |
| Coherus BioSciences currently holds about 275.48 M in cash with (174.88 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 3.54, which can makes it an attractive takeover target, given it will continue generating positive cash flow. | |
| Coherus BioSciences has a frail financial position based on the latest SEC disclosures | |
| Roughly 73.0% of the company shares are held by institutions such as insurance companies |
Coherus BioSciences Upcoming and Recent Events
| 4th of March 2024 Upcoming Quarterly Report | View | |
| 13th of May 2024 Next Financial Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View | |
| 4th of March 2024 Next Fiscal Year End | View | |
| 30th of September 2023 Last Quarter Report | View | |
| 31st of December 2022 Last Financial Announcement | View |
Coherus Largest EPS Surprises
Earnings surprises can significantly impact Coherus BioSciences' stock price both in the short term and over time. Negative earnings surprises usually result in a price decline. However, it has been seen that positive earnings surprises lead to an immediate rise in a stock's price and a gradual increase over time. This is why we often hear news about some companies beating earning projections. Financial analysts spend a large amount of time predicting earnings per share (EPS) along with other important future indicators. Many analysts use forecasting models, management guidance, and additional fundamental information to derive an EPS estimate.
| Reported | Fiscal Date | Estimated EPS | Reported EPS | Surprise | |||
|---|---|---|---|---|---|---|---|
2021-05-06 | 2021-03-31 | 0.07 | 0.01 | -0.06 | 85 | ||
2024-05-09 | 2024-03-31 | -0.24 | -0.32 | -0.08 | 33 | ||
2020-11-05 | 2020-09-30 | 0.41 | 0.33 | -0.08 | 19 |
Coherus Stock Institutional Investors
Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | Morgan Stanley - Brokerage Accounts | 2024-06-30 | 1.6 M | Disciplined Growth Investors Inc | 2024-06-30 | 1.3 M | Cm Management, Llc | 2024-06-30 | 1.1 M | Tang Capital Management Llc | 2024-06-30 | 1.1 M | Tejara Capital Ltd | 2024-06-30 | 1 M | Peregrine Capital Management,llc | 2024-06-30 | 1 M | Jacobs Levy Equity Management, Inc. | 2024-06-30 | 1 M | Alphacentric Advisors, Llc | 2024-06-30 | 1000 K | Northern Trust Corp | 2024-06-30 | 913.7 K | Blackrock Inc | 2024-06-30 | 11.8 M | Vanguard Group Inc | 2024-06-30 | 10.6 M |
Coherus Market Capitalization
The company currently falls under 'Small-Cap' category with a current market capitalization of 101.72 M.Coherus Profitablity
The company has Profit Margin (PM) of (0.1) %, which may suggest that it does not properly executes on its current pricing strategies or is unable to control all of the operational costs. This is way below average. Similarly, it shows Operating Margin (OM) of (0.32) %, which suggests for every $100 dollars of sales, it generated a net operating loss of $0.32.| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (0.43) | (0.45) | |
| Return On Capital Employed | (0.65) | (0.68) | |
| Return On Assets | (0.38) | (0.40) | |
| Return On Equity | 1.23 | 1.97 |
Management Efficiency
Coherus BioSciences has return on total asset (ROA) of (0.1605) % which means that it has lost $0.1605 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (16.5706) %, meaning that it created substantial loss on money invested by shareholders. Coherus BioSciences' management efficiency ratios could be used to measure how well Coherus BioSciences manages its routine affairs as well as how well it operates its assets and liabilities. Return On Equity is likely to gain to 1.97 in 2024, whereas Return On Tangible Assets are likely to drop (0.45) in 2024. At this time, Coherus BioSciences' Non Current Assets Total are comparatively stable compared to the past year. Non Currrent Assets Other is likely to gain to about 74.4 M in 2024, whereas Total Current Assets are likely to drop slightly above 311.1 M in 2024.| Last Reported | Projected for Next Year | ||
| Book Value Per Share | (2.05) | (1.95) | |
| Tangible Book Value Per Share | (2.82) | (2.67) | |
| Enterprise Value Over EBITDA | (3.65) | (3.47) | |
| Price Book Value Ratio | (1.62) | (1.70) | |
| Enterprise Value Multiple | (3.65) | (3.47) | |
| Price Fair Value | (1.62) | (1.70) | |
| Enterprise Value | 691.5 M | 539.3 M |
The analysis of Coherus BioSciences' management efficiency is an essential part of evaluating and assessing the financial and operational performance of the entity. It is also vital to analyze Coherus BioSciences' future growth prospects and the overall market conditions to determine the value and potential of its stock. The analysis involves studying a range of financial metrics such as revenue, earnings, profit margins, cash flow, debt, market share, and external factors such as economic trends, industry outlook, competition, and government regulations. The goal of Coherus Stock analysis is to determine whether it is undervalued, fairly valued, or overvalued and to make informed investment decisions.
Operating Margin (0.32) | Profit Margin (0.1) | Beta 0.654 | Return On Assets (0.16) | Return On Equity (16.57) |
Technical Drivers
As of the 20th of October, Coherus BioSciences shows the Mean Deviation of 4.06, standard deviation of 5.62, and Risk Adjusted Performance of (0.09). Coherus BioSciences technical analysis gives you the methodology to make use of historical prices and volume patterns to determine a pattern that approximates the direction of the firm's future prices. Please confirm Coherus BioSciences mean deviation, treynor ratio, as well as the relationship between the Treynor Ratio and kurtosis to decide if Coherus BioSciences is priced correctly, providing market reflects its regular price of 0.88 per share. Given that Coherus BioSciences is a hitting penny stock territory we recommend to closely look at its jensen alpha.Coherus BioSciences Price Movement Analysis
The output start index for this execution was thirteen with a total number of output elements of fourty-eight. The Bollinger Bands is very popular indicator that was developed by John Bollinger. It consist of three lines. Coherus BioSciences middle band is a simple moving average of its typical price. The upper and lower bands are (N) standard deviations above and below the middle band. The bands widen and narrow when the volatility of the price is higher or lower, respectively. The upper and lower bands can also be interpreted as price targets for Coherus BioSciences. When the price bounces off of the lower band and crosses the middle band, then the upper band becomes the price target.
Coherus BioSciences Insider Trading Activities
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Coherus BioSciences insiders, such as employees or executives, is commonly permitted as long as it does not rely on Coherus BioSciences' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Coherus BioSciences insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Coherus BioSciences Outstanding Bonds
Coherus BioSciences issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. Coherus BioSciences uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most Coherus bonds can be classified according to their maturity, which is the date when Coherus BioSciences has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.
| CCOI 7 15 JUN 27 Corp BondUS19240CAE30 | View | |
| US19240CAC73 Corp BondUS19240CAC73 | View | |
| MPLX LP 4125 Corp BondUS55336VAK61 | View | |
| Morgan Stanley 3591 Corp BondUS61744YAK47 | View |
Coherus BioSciences Predictive Daily Indicators
Coherus BioSciences intraday indicators are useful technical analysis tools used by many experienced traders. Just like the conventional technical analysis, daily indicators help intraday investors to analyze the price movement with the timing of Coherus BioSciences stock daily movement. By combining multiple daily indicators into a single trading strategy, you can limit your risk while still earning strong returns on your managed positions.
Coherus BioSciences Forecast Models
Coherus BioSciences' time-series forecasting models are one of many Coherus BioSciences' stock analysis techniques aimed at predicting future share value based on previously observed values. Time-series forecasting models ae widely used for non-stationary data. Non-stationary data are called the data whose statistical properties e.g. the mean and standard deviation are not constant over time but instead, these metrics vary over time. These non-stationary Coherus BioSciences' historical data is usually called time-series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the market movement and maximize returns from investment trading.About Coherus Stock Analysis
Stock analysis is the technique used by a trader or investor to examine and evaluate how Coherus BioSciences prices is reacting to, or reflecting on a current market direction and economic conditions. It can be used to make informed decisions about market timing, and when buying or selling Coherus shares will generate the highest return on investment. We also built our stock analysis module to help investors to gain an insight into the world economy as a whole, the stock market, thematic ideas. a specific sector, or an individual Stock such as Coherus BioSciences. By using and applying Coherus Stock analysis, traders can create a robust methodology for identifying Coherus entry and exit points for their positions.
| Last Reported | Projected for Next Year | ||
| Pretax Profit Margin | (0.93) | (0.97) | |
| Operating Profit Margin | (0.75) | (0.79) | |
| Net Loss | (0.92) | (0.97) | |
| Gross Profit Margin | 0.37 | 0.39 |
Current Coherus Analysis - Recommendations
We track the performance of the top 100 financial experts across various large and mid-size financial boutiques. Coherus analyst recommendations are determined by taking all analyst recommendations and averaging them as Strong Buy, Buy, Hold, Strong Sell or Sell. There is no one specific way to measure analysis performance other than comparing it to the past results via a very sophisticated attribution analysis. Coherus analyst consensus and target price projections should be used in combination with other traditional techniques such as stock price forecasting, technical analysis, earnings estimate, and various momentum models.
| Target Price | Advice | # of Analysts | |
| 12.63 | Strong Buy | 9 | Odds |
Most Coherus analysts issue ratings four times a year, at intervals of three months. Ratings are usually accompanied by a target price to helps potential investors understand Coherus stock's fair price compared to its market value. Analysts arrive at stock ratings after researching public financial statements of Coherus BioSciences, talking to its executives and customers, or listening to Coherus conference calls.
Coherus Stock Analysis Indicators
Coherus BioSciences stock analysis indicators help investors evaluate how Coherus BioSciences stock reacts to ongoing and evolving market conditions. The investors can use it to make informed decisions about market timing and determine when trading Coherus BioSciences shares will generate the highest return on investment. By understating and applying Coherus BioSciences stock analysis, traders can identify Coherus BioSciences position entry and exit signals to maximize returns.
| Begin Period Cash Flow | 63.5 M | |
| Long Term Debt | 473.4 M | |
| Common Stock Shares Outstanding | 94.2 M | |
| Total Stockholder Equity | -193.4 M | |
| Tax Provision | -380 K | |
| Quarterly Earnings Growth Y O Y | -0.755 | |
| Property Plant And Equipment Net | 11 M | |
| Cash And Short Term Investments | 117.7 M | |
| Cash | 102.9 M | |
| Accounts Payable | 35.2 M | |
| Net Debt | 378 M | |
| 50 Day M A | 1.1807 | |
| Total Current Liabilities | 331.8 M | |
| Other Operating Expenses | 450.4 M | |
| Non Current Assets Total | 154 M | |
| Forward Price Earnings | 6.7981 | |
| Non Currrent Assets Other | 70.8 M | |
| Stock Based Compensation | 43.1 M |
Additional Tools for Coherus Stock Analysis
When running Coherus BioSciences' price analysis, check to measure Coherus BioSciences' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Coherus BioSciences is operating at the current time. Most of Coherus BioSciences' value examination focuses on studying past and present price action to predict the probability of Coherus BioSciences' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Coherus BioSciences' price. Additionally, you may evaluate how the addition of Coherus BioSciences to your portfolios can decrease your overall portfolio volatility.